Functional polymorphisms in the matrix metalloproteinase genes and their association with bladder cancer risk and recurrence: A mini-review

International Journal of Urology

Volumn 21, Issue 8, 2014, Pages 744-752

  Wieczorek, Edyta ^a   Wasowicz, Wojciech ^a   Gromadzinska, Jolanta ^a   Reszka, Edyta ^a  

^a NOFER INSTITUTE OF OCCUPATIONAL MEDICINE   (Poland)

Author keywords

Bladder cancer; Genetic polymorphisms; Matrix metalloproteinases; Recurrence; Risk

Indexed keywords

GELATINASE A; GELATINASE B; INTERSTITIAL COLLAGENASE; MACROPHAGE ELASTASE; MATRILYSIN; MATRIX METALLOPROTEINASE; NEUTROPHIL COLLAGENASE; STROMELYSIN; TUMOR MARKER;

ALLELE; BLADDER CANCER; CANCER PATIENT; CANCER PROGNOSIS; CANCER RECURRENCE; CANCER RISK; CANCER SURVIVAL; GENETIC ASSOCIATION; GENETIC POLYMORPHISM; HAPLOTYPE; HUMAN; PRIORITY JOURNAL; PROMOTER REGION; RECURRENCE FREE SURVIVAL; REVIEW; SINGLE NUCLEOTIDE POLYMORPHISM; TUMOR INVASION; BLADDER; BLADDER TUMOR; GENETIC PREDISPOSITION; GENETICS; PATHOLOGY; TUMOR RECURRENCE;

GENETIC PREDISPOSITION TO DISEASE; HAPLOTYPES; HUMANS; MATRIX METALLOPROTEINASES; NEOPLASM INVASIVENESS; NEOPLASM RECURRENCE, LOCAL; POLYMORPHISM, GENETIC; TUMOR MARKERS, BIOLOGICAL; URINARY BLADDER; URINARY BLADDER NEOPLASMS;

EID: 84904862050     PISSN: 09198172     EISSN: 14422042     Source Type: Journal    
DOI: 10.1111/iju.12431     Document Type: Review

References (105)

1. Jemal A, Bray F, Center MM, Ferlay J, Ward E, Forman D. Global cancer statistics. CA Cancer J. Clin. 2010; 61: 69-90.
2. Parkin DM. The global burden of urinary bladder cancer. Scand. J. Urol. Nephrol. Suppl. 2008; 218: 12-20.
3. Herr HW. Tumor progression and survival of patients with high grade, noninvasive papillary (TaG3) bladder tumors: 15-year outcome. J. Urol. 2000; 163: 60-61.
4. Mitra AP, Datar RH, Cote RJ. Molecular pathways in invasive bladder cancer: new insights into mechanisms, progression, and target identification. J. Clin. Oncol. 2006; 35: 5552-5564.
5. Bolenz C, Lotan Y. Translational research in bladder cancer: from molecular pathogenesis to useful tissue biomarkers. Cancer Biol. Ther. 2010; 10: 407-415.
6. Parks WC, Shapiro SD. Matrix metalloproteinases in lung biology. Respir. Res. 2001; 2: 10-19.
7. Johansson N, Ahonen M, Kähäri VM. Matrix metalloproteinases in tumor invasion. Cell. Mol. Life Sci. 2000; 57: 5-15.
8. Egeblad M, Werb Z. New functions for the matrix metalloproteinases in cancer progression. Nat. Rev. Cancer 2002; 3: 161-174.
9. Goldring MB, Marcu KB. Cartilage homeostasis in health and rheumatic diseases. Arthritis Res. Ther. 2009; 11: 224-240.
10. Bäck M, Ketelhuth DF, Agewall S. Matrix metalloproteinases in atherothrombosis. Prog. Cardiovasc. Dis. 2010; 52: 410-428.
11. Gross J, Lapiere CM. Collagenolytic activity in amphibian tissues: a tissue culture assay. Proc. Natl. Acad. Sci. U.S.A. 1962; 48: 1014-1022.
12. Liotta LA, Tryggvason K, Garbisa S, Hart I, Foltz CM, Shafie S. Metastatic potential correlates with enzymatic degradation of basement membrane collagen. Nature 1980; 5751: 67-68.
13. Overall CM. Molecular determinants of metalloproteinase substrate specificity: matrix metalloproteinase substrate binding domains, modules, and exosites. Mol. Biotechnol. 2002; 22: 51-86.
14. Activation NH. mechanisms of matrix metalloproteinases. Biol. Chem. 1997; 378: 151-160.
15. Westermarck J, Kähäri VM. Regulation of matrix metalloproteinase expression in tumor invasion. FASEB J. 1999; 13: 781-792.
16. Nagase H, Woessner JF. Matrix metalloproteinases. J. Biol. Chem. 1999; 274: 21491-21494.
17. Brew K, Dinakarpandian D, Nagase H. Tissue inhibitors of metalloproteinases: evolution, structure and function. Biochim. Biophys. Acta 2000; 1477: 267-283.
18. Maskos K, Bode W. Structural basis of matrix metalloproteinases and tissue inhibitors of metalloproteinases. Mol. Biotechnol. 2003; 25: 241-266.
19. Mackay AR, Hartzler JL, Pelina MD, Thorgeirsson UP. Studies on the ability of 65-kDa and 92-kDa tumor cell gelatinases to degrade type IV collagen. J. Biol. Chem. 1990; 265: 21929-21934.
20. McQuibban GA, Gong JH, Tam EM, McCulloch CA, Clark-Lewis I, Overall CM. Inflammation dampened by gelatinase A cleavage of monocyte chemoattractant protein-3. Science 2000; 5482: 1202-1206.
21. Levi E, Fridman R, Miao HQ, Ma YS, Yayon A, Vlodavsky I. Matrix metalloproteinase 2 releases active soluble ectodomain of fibroblast growth factor receptor 1. Proc. Natl. Acad. Sci. U.S.A. 1996; 93: 7069-7074.
22. Yu Q, Stamenkovic I. Cell surface-localized matrix metalloproteinase-9 proteolytically activates TGF-beta and promotes tumor invasion and angiogenesis. Genes Dev. 2000; 14: 163-176.
23. McCawley LJ, Matrisian LM. Matrix metalloproteinases: they're not just for matrix anymore! Curr. Opin. Cell Biol. 2001; 13: 534-540.
24. Konstantinopoulos PA, Karamouzis MV, Papatsoris AG, Papavassiliou AG. Matrix metalloproteinase inhibitors as anticancer agents. Int. J. Biochem. Cell Biol. 2008; 40: 1156-1168.
25. Cattoretti G, Becker MH, Key G etal. Monoclonal antibodies against recombinant parts of the Ki-67 antigen (MIB 1 and MIB 3) detect proliferating cells in microwave-processed formalin-fixed paraffin sections. J. Pathol. 1992; 168: 357-363.
26. Canesin G, Gonzalez-Peramato P, Palou J, Urrutia M, Cordón-Cardo C, Sánchez-Carbayo M. Galectin-3 expression is associated with bladder cancer progression and clinical outcome. Tumour Biol. 2010; 31: 277-285.
27. Shariat SF, Tokunaga H, Zhou J etal. p53, p21, pRB, and p16 expression predict clinical outcome in cystectomy with bladder cancer. J. Clin. Oncol. 2004; 22: 1014-1024.
28. Chatterjee SJ, Datar R, Youssefzadeh D etal. Combined effects of p53, p21, and pRb expression in the progression of bladder transitional cell carcinoma. J. Clin. Oncol. 2004; 22: 1007-1013.
29. Shariat SF, Karakiewicz PI, Ashfaq R etal. Multiple biomarkers improve prediction of bladder cancer recurrence and mortality in patients undergoing cystectomy. Cancer 2008; 112: 315-325.
30. Shariat SF, Ashfaq R, Sagalowsky AI, Lotan Y. Predictive value of cell cycle biomarkers in nonmuscle invasive bladder transitional cell carcinoma. J. Urol. 2007; 177: 481-487.
31. Shariat SF, Ashfaq R, Sagalowsky AI, Lotan Y. Association of cyclin D1 and E1 expression with disease progression and biomarkers in patients with nonmuscle-invasive urothelial cell carcinoma of the bladder. Urol. Oncol. 2007; 25: 468-475.
32. Scorilas A, Karameris A, Arnogiannaki N etal. Overexpression of matrix-metalloproteinase-9 in human breast cancer: a potential favourable indicator in node-negative patients. Br. J. Cancer 2001; 84: 1488-1496.
33. Shariat SF, Ashfaq R, Karakiewicz PI, Saeedi O, Sagalowsky AI, Lotan Y. Survivin expression is associated with bladder cancer presence, stage, progression, and mortality. Cancer 2007; 109: 1106-1113.
34. Karam JA, Lotan Y, Karakiewicz PI etal. Use of combined apoptosis biomarkers for prediction of bladder cancer recurrence and mortality after radical cystectomy. Lancet Oncol. 2007; 8: 128-136.
35. Syrigos KN, Krausz T, Waxman J etal. E-cadherin expression in bladder cancer using formalin-fixed, paraffin-embedded tissues: correlation with histopathological grade, tumour stage and survival. Int. J. Cancer 1995; 64: 367-370.
36. Staack A, Badendieck S, Schnorr D, Loening SA, Jung K. Combined determination of plasma MMP2, MMP9, and TIMP1 improves the non-invasive detection of transitional cell carcinoma of the bladder. BMC Urol. 2006; 6: 19.
37. Hadler-Olsen E, Winberg JO, Uhlin-Hansen L. Matrix metalloproteinases in cancer: their value as diagnostic and prognostic markers and therapeutic targets. Tumour Biol. 2013; 34: 2041-2051.
38. Roy R, Yang J, Moses MA. Matrix metalloproteinases as novel biomarkers and potential therapeutic targets in human cancer. J. Clin. Oncol. 2009; 31: 5287-5297.
39. Eissa S, Badr S, Elhamid SA, Helmy AS, Nour M, Esmat M. The value of combined use of survivin mRNA and matrix metalloproteinase 2 and 9 for bladder cancer detection in voided urine. Dis. Markers 2013; 34: 57-62.
40. Rodriguez Faba O, Palou-Redorta J, Fernández-Gómez JM etal. Matrix metalloproteinases and bladder cancer: what is new? ISRN Urol. 2012; 2012: 581539.
41. Mohammed MA, Seleim MF, Abdalla MS, Sharada HM, Abdel Wahab AH. Urinary high molecular weight matrix metalloproteinases as non-invasive biomarker for detection of bladder cancer. BMC Urol. 2013; 13: 25.
42. Sapre N, Anderson PD, Costello AJ, Hovens CM, Corcoran NM. Gene-based urinary biomarkers for bladder cancer: an unfulfilled promise? Urol. Oncol. 2014; 32: 48.
43. Rothman N, Garcia-Closas M, Chatterjee N etal. A multi-stage genome-wide association study of bladder cancer identifies multiple susceptibility loci. Nat. Genet. 2010; 42: 978-984.
44. Figueroa JD, Ye Y, Siddiq A etal. Genome-wide association study identifies multiple loci associated with bladder cancer risk. Hum. Mol. Genet. 2013; 23: 1387-1398.
45. Haq I, Chappell S, Johnson SR etal. Association of MMP-2 polymorphisms with severe and very severe COPD: a case control study of MMPs-1, 9 and 12 in a European population. BMC Med. Genet. 2010; 15: 7.
46. González-Arriaga P, Pascual T, García-Alvarez A etal. Genetic polymorphisms in MMP 2, 9 and 3 genes modify lung cancer risk and survival. BMC Cancer 2012; 28: 121.
47. Szarvas T, vom Dorp F, Ergün S, Rübben H. Matrix metalloproteinases and their clinical relevance in urinary bladder cancer. Nat. Rev. Urol. 2011; 8: 241-254.
48. Terry CF, Loukaci V, Green FR. Cooperative influence of genetic polymorphisms on interleukin 6 transcriptional regulation. J. Biol. Chem. 2000; 275: 18138-18144.
49. Pearce E, Tregouet DA, Samnegård A etal. Haplotype effect of the matrix metalloproteinase-1 gene on risk of myocardial infarction. Circ. Res. 2005; 97: 1070-1076.
50. Biondi ML, Turri O, Leviti S etal. MMP1 and MMP3 polymorphisms in promoter regions and cancer. Clin. Chem. 2000; 46: 2023-2024.
51. Ghilardi G, Biondi ML, Mangoni J etal. Matrix metalloproteinase-1 promoter polymorphism 1G/2G is correlated with colorectal cancer invasiveness. Clin. Cancer Res. 2001; 8: 2344-2346.
52. Zhu Y, Spitz MR, Lei L, Mills GB, Wu X. A single nucleotide polymorphism in the matrix metalloproteinase-1 promoter enhances lung cancer susceptibility. Cancer Res. 2001; 61: 7825-7829.
53. Ghilardi G, Biondi ML, Caputo M etal. A single nucleotide polymorphism in the matrix metalloproteinase-3 promoter enhances breast cancer susceptibility. Clin. Cancer Res. 2002; 12: 3820-3823.
54. Hinoda Y, Okayama N, Takano N etal. Association of functional polymorphisms of matrix metalloproteinase (MMP)-1 and MMP-3 genes with colorectal cancer. Int. J. Cancer 2002; 102: 526-529.
55. Xu E, Lai M, Lv B, Xing X, Huang Q, Xia XA. single nucleotide polymorphism in the matrix metalloproteinase-2 promoter is associated with colorectal cancer. Biochem. Biophys. Res. Commun. 2004; 324: 999-1003.
56. Fang S, Jin X, Wang R etal. Polymorphisms in the MMP1 and MMP3 promoter and non-small cell lung carcinoma in North China. Carcinogenesis 2005; 26: 481-486.
57. Zhou Y, Yu C, Miao X etal. Functional haplotypes in the promoter of matrix metalloproteinase-2 and lung cancer susceptibility. Carcinogenesis 2005; 26: 1117-1121.
58. Elander N, Söderkvist P, Fransén K. Matrix metalloproteinase (MMP) -1, -2, -3 and -9 promoter polymorphisms in colorectal cancer. Anticancer Res. 2006; 26: 791-795.
59. Lei H, Hemminki K, Altieri A etal. Promoter polymorphisms in matrix metalloproteinases and their inhibitors: few associations with breast cancer susceptibility and progression. Breast Cancer Res. Treat. 2007; 103: 61-69.
60. Rutter JL, Mitchell TI, Butticè G etal. A single nucleotide polymorphism in the matrix metalloproteinase-1 promoter creates an Ets binding site and augments transcription. Cancer Res. 1998; 58: 5321-5325.
61. Ye S, Eriksson P, Hamsten A etal. Progression of coronary atherosclerosis is associated with a common genetic variant of the human stromelysin-1 promoter which results in reduced gene expression. J. Biol. Chem. 1996; 271: 13055-13060.
62. Tower GB, Coon CC, Benbow U, Vincenti MP, Brinckerhoff CE. Erk 1/2 differentially regulates the expression from the 1G/2G single nucleotide polymorphism in the MMP-1 promoter in melanoma cells. Biochim. Biophys. Acta 2002; 1586: 265-274.
63. Krippl P, Langsenlehner U, Renner W etal. The 5A/6A polymorphism of the matrix metalloproteinase 3 gene promoter and breast cancer. Clin. Cancer Res. 2004; 10: 3518-3520.
64. Zhang B, Ye S, Herrmann SM etal. Functional polymorphism in the regulatory region of gelatinase B gene in relation to severity of coronary atherosclerosis. Circulation 1999; 99: 1788-1794.
65. Price SJ, Greaves DR, Watkins H. Identification of novel, functional genetic variants in the human matrix metalloproteinase-2 gene: role of Sp1 in allele-specific transcriptional regulation. J. Biol. Chem. 2001; 276: 7549-7558.
66. Jormsjö S, Ye S, Moritz J etal. Allele-specific regulation of matrix metalloproteinase-12 gene activity is associated with coronary artery luminal dimensions in diabetic patients with manifest coronary artery disease. Circ. Res. 2000; 86: 998-1003.
67. Vasků V, Vasků A, Tschöplová S, Izakovicová Hollá L, Semrádová V, Vácha J. Genotype association of C(-735)T polymorphism in matrix metalloproteinase 2 gene with G(8002)A endothelin 1 gene with plaque psoriasis. Dermatology 2002; 204: 262-265.
68. Wang H, Parry S, Macones G etal. Functionally significant SNP MMP8 promoter haplotypes and preterm premature rupture of membranes (PPROM). Hum. Mol. Genet. 2004; 21: 2659-2669.
69. Zhang J, Jin X, Fang S etal. The functional polymorphism in the matrix metalloproteinase-7 promoter increases susceptibility to esophageal squamous cell carcinoma, gastric cardiac adenocarcinoma and non-small cell lung carcinoma. Carcinogenesis 2005; 26: 1748-1753.
70. Decock J, Long JR, Laxton RC etal. Association of matrix metalloproteinase-8 gene variation with breast cancer prognosis. Cancer Res. 2007; 67: 10214-10221.
71. Fiotti N, Altamura N, Fisicaro M etal. MMP-9 microsatellite polymorphism and susceptibility to carotid arteries atherosclerosis. Arterioscler. Thromb. Vasc. Biol. 2006; 26: 1330-1336.
72. Lee YJ, Kang SW, Baek HJ etal. Association between matrix metalloproteinase 9 promoter polymorphisms and Behçet's disease. Hum. Immunol. 2010; 71: 717-722.
73. Peters DG, Kassam A, St Jean PL, Yonas H, Ferrell RE. Functional polymorphism in the matrix metalloproteinase-9 promoter as a potential risk factor for intracranial aneurysm. Stroke 1999; 30: 2612-2616.
74. Shimajiri S, Arima N, Tanimoto A etal. Shortened microsatellite d(CA)21 sequence down-regulates promoter activity of matrix metalloproteinase 9 gene. FEBS Lett. 1999; 455: 70-74.
75. Fornoni A, Wang Y, Lenz O, Striker LJ, Striker GE. Association of a decreased number of d(CA) repeats in the matrix metalloproteinase-9 promoter with glomerulosclerosis susceptibility in mice. J. Am. Soc. Nephrol. 2002; 13: 2068-2076.
76. Huang TS, Lee CC, Chang AC etal. Shortening of microsatellite deoxy(CA) repeats involved in GL331-induced down-regulation of matrix metalloproteinase-9 gene expression. Biochem. Biophys. Res. Commun. 2003; 300: 901-907.
77. Clark IM, Swingler TE, Sampieri CL etal. The regulation of matrix metalloproteinases and their inhibitors. Int. J. Biochem. Cell Biol. 2008; 40: 1362-1378.
78. Fanjul-Fernández M, Folgueras AR, Cabrera S, López-Otín C. Matrix metalloproteinases: evolution, gene regulation and functional analysis in mouse models. Biochim. Biophys. Acta 2010; 1803: 3-19.
79. Kader AK, Shao L, Dinney CP etal. Matrix metalloproteinase polymorphisms and bladder cancer risk. Cancer Res. 2006; 66: 11644-11648.
80. Kader AK, Liu J, Shao L etal. Matrix metalloproteinase polymorphisms are associated with bladder cancer invasiveness. Clin. Cancer Res. 2007; 13: 2614-2620.
81. Tasci AI, Tugcu V, Ozbek E, Ozbay B, Simsek A, Koksal V. A single-nucleotide polymorphism in the matrix metalloproteinase-1 promoter enhances bladder cancer susceptibility. BJU Int. 2008; 101: 503-507.
82. Srivastava P, Gangwar R, Kapoor R, Mittal RD. Bladder cancer risk associated with genotypic polymorphism of the matrix metalloproteinase-1 and 7 in North Indian population. Dis. Markers 2010; 29: 37-46.
83. Wieczorek E, Reszka E, Jablonowski Z etal. Genetic polymorphisms in matrix metalloproteinases (MMPs) and tissue inhibitors of MPs (TIMPs), and bladder cancer susceptibility. BJU Int. 2013; 112: 1207-1214.
84. Srivastava P, Kapoor R, Mittal RD. Association of single nucleotide polymorphisms in promoter of matrix metalloproteinase-2, 8 genes with bladder cancer risk in Northern India. Urol. Oncol. 2013; 31: 247-254.
85. Srivastava P, Mandhani A, Kapoor R, Mittal RD. Role of MMP-3 and MMP-9 and their haplotypes in risk of bladder cancer in North Indian cohort. Ann. Surg. Oncol. 2010; 17: 3068-3075.
86. Wieczorek E, Reszka E, Wasowicz W etal. MMP MMP7 and MMP8 genetic polymorphisms in bladder cancer patients. Cent. Eur. J. Urol. 2013; 66: 405-410.
87. Herr HW, Schwalb DM, Zhang ZF etal. Intravesical bacillus Calmette-Guérin therapy prevents tumor progression and death from superficial bladder cancer: ten-year follow-up of a prospective randomized trial. J. Clin. Oncol. 1995; 13: 1404-1408.
88. Sylvester RJ, van der Meijden AP, Lamm DL. Intravesical bacillus Calmette-Guerin reduces the risk of progression in patients with superficial bladder cancer: a meta-analysis of the published results of randomized clinical trials. J. Urol. 2002; 168: 1964-1970.
89. Sylvester RJ, van der Meijden AP, Oosterlinck W etal. Predicting recurrence and progression in individual patients with stage Ta T1 bladder cancer using EORTC risk tables: a combined analysis of 2596 patients from seven EORTC trials. Eur. Urol. 2006; 49: 466-477.
90. Bensalah K, Montorsi F, Shariat SF. Challenges of cancer biomarker profiling. Eur. Urol. 2007; 52: 1601-1609.
91. Anastasiadis A, de Reijke TM. Best practice in the treatment of nonmuscle invasive bladder cancer. Ther. Adv. Urol. 2012; 4: 13-32.
92. Hiyama T, Yoshihara M, Tanaka S, Chayama K. Genetic polymorphisms and head and neck cancer risk (Review). Int. J. Oncol. 2008; 32: 945-973.
93. Decock J, Paridaens R, Ye S. Genetic polymorphisms of matrix metalloproteinases in lung, breast and colorectal cancer. Clin. Genet. 2008; 73: 197-211.
94. O'Mara TA, Clements JA, Spurdle AB. The use of predictive or prognostic genetic biomarkers in endometrial and other hormone-related cancers: justification for extensive candidate gene single nucleotide polymorphism studies of the matrix metalloproteinase family and their inhibitors. Cancer Epidemiol. Biomarkers Prev. 2009; 18: 2352-2365.
95. McColgan P, Sharma P. Polymorphisms of matrix metalloproteinases 1, 2, 3 and 9 and susceptibility to lung, breast and colorectal cancer in over 30, 000 subjects. Int. J. Cancer 2009; 125: 1473-1478.
96. Peng B, Cao L, Ma X, Wang W, Wang D, Yu L. Meta-analysis of association between matrix metalloproteinases 2, 7 and 9 promoter polymorphisms and cancer risk. Mutagenesis 2010; 25: 371-379.
97. Peng B, Cao L, Wang W etal. Polymorphisms in the promoter regions of matrix metalloproteinases 1 and 3 and cancer risk: a meta-analysis of 50 case-control studies. Mutagenesis 2010; 25: 41-48.
98. Shishodia S, Potdar P, Gairola CG, Aggarwal BB. Curcumin (diferuloylmethane) down-regulates cigarette smoke-induced NF-kappaB activation through inhibition of IkappaBalpha kinase in human lung epithelial cells: correlation with suppression of COX-2, MMP-9 and cyclin D1. Carcinogenesis 2003; 24: 1269-1279.
99. Chen W, Li Z, Bai L, Lin Y. NF-kappaB in lung cancer, a carcinogenesis mediator and a prevention and therapy target. Front. Biosci. (Landmark Ed) 2011; 16: 1172-1185.
100. Mercer BA, Kolesnikova N, Sonett J, D'Armiento J. Extracellular regulated kinase/mitogen activated protein kinase is up-regulated in pulmonary emphysema and mediates matrix metalloproteinase-1 induction by cigarette smoke. J. Biol. Chem. 2004; 279: 17690-17696.
101. Mercer B, Brinckerhoff C, D'Armiento J. Activation of the MMP-1 promoter by cigarette smoke in human small airway epithelial cells requires ERK MAP kinase signaling: differential response of the 1G and 2G promoter sequences. Proc. Am. Thorac. Soc. 2006; 6: 477.
102. Garcia-Closas M, Rothman N, Figueroa JD etal. Common genetic polymorphisms modify the effect of smoking on absolute risk of bladder cancer. Cancer Res. 2013; 73: 2211-2220.
103. Rothman N, Wacholder S, Caporaso NE etal. The use of common genetic polymorphisms to enhance the epidemiologic study of environmental carcinogens. Biochim. Biophys. Acta 2001; 1471: C1-10.
104. Pelucchi C, Bosetti C, Negri E etal. Mechanisms of disease: the epidemiology of bladder cancer. Nat. Clin. Pract. Urol. 2006; 6: 327-340.
105. Xie Q, Ratnasinghe LD, Hong H etal. Decision forest analysis of 61 single nucleotide polymorphisms in a case-control study of esophageal cancer; a novel method. BMC Bioinformatics 2005; 6 (Suppl 2): S4.